EBV gB Function in Viral Fusion, Entry, and Egress
EBV gB Function in Viral Fusion, Entry, and Egress
批准号:
7340207
负责人:
Richard M Longnecker
金额:
$36.56万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-01-15 至 2011-12-31
关键词:
AIDS-Related Opportunistic InfectionsAcquired Immunodeficiency SyndromeAntibodiesB-LymphocytesBindingBiological AssayCapsidCell Surface ReceptorsCell fusionCell surfaceCellsChimeric ProteinsClassComplement 3d ReceptorsCytoplasmic TailCytoskeletonDevelopmentDiseaseEBV-associated diseaseEpithelialEpithelial CellsEpithelial Receptor CellEpstein-Barr Virus InfectionsExpression LibraryFamilyGlycoproteinsGoalsGolgi ApparatusGreen Fluorescent ProteinsGuanineGuanine Nucleotide Exchange FactorsHerpesviridaeHumanHuman Herpesvirus 4ImmuneImmunoprecipitationInfectionKnowledgeLaboratoriesLymphoidMaintenanceMalignant - descriptorMalignant NeoplasmsMediatingMolecularMonitorMonoclonal AntibodiesMorphogenesisMutationPatientsPeripheralPhenotypePredispositionProcessPropertyProtein BindingProteinsRecombinantsRegulationResearchRoleScreening procedureSimplexvirusSiteSpecificityTailTherapeuticTissuesTropismViralViral ProteinsVirionVirusVirus-Induced Membrane FusionWorkYeastsbasecDNA Expressioncell typein vivoinsightmutantnovelras-Related G-Proteinsreceptorreceptor functionresearch studytissue tropismtooltraffickingyeast two hybrid system
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The understanding of the molecular basis of Epstein-Barr virus (EBV)entry into target cells and virion
trafficking in infected cells is the long-term goal of the Lonanecker Laboratory. We anticipate that discoveries
related to EBV entry and virion morphogenesis in infected cells will be important for the development of
therapeutics to treat EBV-associated cancers in the human host. Our overall hypothesis that drives our
research focus is that EBV gB interacts with specific cell surface receptors that facilitate viral fusion and
entry into EBV target cells. In addition, the cytoplasmic tail of EBV gB interacts with host and viral proteins
and this interaction is important for regulating fusion, but also required for proper egress of EBV capsids from
infected cells. The tissue tropism for EBV in vivo is largely limited to cells of epithelial or lymphoid origin.
The cellular and viral factors required for EBV entry of target B cells has been fairly well described. The
major viral envelope glycoprotein 350/220 (gp350/220) binds to CR2/CD21 that is abundantly expressed on
B cells. Subsequently, gp42 binds to HLA Class II triggering fusion mediated by gB and gH/gL. Few details
are known in regard to the mechanism of EBV induced membrane fusion and viral entry into epithelial cells.
It is apparent that other receptors function in epithelial cells since CD21 and HLA Class II are not typically
expressed on epithelial cells. Lindsey Hutt-Fletcher has provided compelling evidence to suggest that EBV
entry of epithelial cells when compared to B cells is mechanistically different. In our preliminary studies, we
have shown that in contrast to B cells, which require gp42, gB, and gH/gL for efficient cell fusion, epithelial
cells require only gB, and gH/gL and when a mutant form of gB is used, only gB is required for efficient cell
fusion indicating that gB may be the major fusion protein for epithelial cells and that a specific epithelial
receptor for gB may exist. This proposal will analyze:
1 - The role of gB in EBV entry of epithelial and B cells by the identification of important gB functional
domains by site-specific and random mutation.
2 - The role of the gB cytoplasmic tail in regulating fusion and mediating virion morphogenesis as well as the
function of several cellular proteins that bind the gB tail will be determined.
3 - The existence of a novel gB receptor will be investigated.
Clarifying the interactions between EBV and target cells is essential for understanding the tropism of EBV
infections in the human host. Knowledge of the mechanism and viral and cellular factors required for EBV
entry and replication in epithelial and B cells will provide insight into host susceptibility and will allow for the
development of therapeutics for the treatment or eradication of EBV-associated diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Receptor Usage and Regulation of the Immune Response in HSV Infection
-
批准号:10738934
-
项目类别:
-
资助金额:$23.5万
-
财政年份:2023
-
负责人:Richard M Longnecker
-
依托单位:
Role of Host Cell Factors in Newborn Herpes Simplex Virus (HSV) Encephalitis
-
批准号:10133167
-
项目类别:
-
资助金额:$32.82万
-
财政年份:2019
-
负责人:Richard M Longnecker
-
依托单位:
Role of Host Cell Factors in Newborn Herpes Simplex Virus (HSV) Encephalitis
-
批准号:10369050
-
项目类别:
-
资助金额:$32.73万
-
财政年份:2019
-
负责人:Richard M Longnecker
-
依托单位:
Role of Host Cell Factors in Newborn Herpes Simplex Virus (HSV) Encephalitis
-
批准号:10589755
-
项目类别:
-
资助金额:$32.64万
-
财政年份:2019
-
负责人:Richard M Longnecker
-
依托单位:
Role of Host Cell Factors in Newborn Herpes Simplex Virus (HSV) Encephalitis
-
批准号:9890025
-
项目类别:
-
资助金额:$32.9万
-
财政年份:2019
-
负责人:Richard M Longnecker
-
依托单位:
Role of Host Cell Factors in Herpes Simplex Virus (HSV) Keratitis
-
批准号:8029319
-
项目类别:
-
资助金额:$22.88万
-
财政年份:2011
-
负责人:Richard M Longnecker
-
依托单位:
Role of Host Cell Factors in Herpes Simplex Virus (HSV) Keratitis
-
批准号:8232012
-
项目类别:
-
资助金额:$19.06万
-
财政年份:2011
-
负责人:Richard M Longnecker
-
依托单位:
Discovery of New Treatment Options for EBV-associated Lymphoma and PTLD
-
批准号:8245223
-
项目类别:
-
资助金额:$7.96万
-
财政年份:2008
-
负责人:Richard M Longnecker
-
依托单位:
Discovery of New Treatment Options for EBV-associated Lymphoma and PTLD
-
批准号:8267730
-
项目类别:
-
资助金额:$27.35万
-
财政年份:2008
-
负责人:Richard M Longnecker
-
依托单位:
DETERMINATION OF THE IMPORTANCE OF LMP2A IN PRIMARY EBV INFECTION
-
批准号:7715494
-
项目类别:
-
资助金额:$23.79万
-
财政年份:2008
-
负责人:Richard M Longnecker
-
依托单位:
Discovery of New Treatment Options for EBV-associated Lymphoma and PTLD
-
批准号:8076396
-
项目类别:
-
资助金额:$40.24万
-
财政年份:2008
-
负责人:Richard M Longnecker
-
依托单位:
Discovery of New Treatment Options for EBV-associated Lymphoma and PTLD
-
批准号:8396649
-
项目类别:
-
资助金额:$7.94万
-
财政年份:2008
-
负责人:Richard M Longnecker
-
依托单位:
Discovery of New Treatment Options for EBV-associated Lymphoma and PTLD
-
批准号:7657371
-
项目类别:
-
资助金额:$27.42万
-
财政年份:2008
-
负责人:Richard M Longnecker
-
依托单位:
Discovery of New Treatment Options for EBV-associated Lymphoma and PTLD
-
批准号:8104843
-
项目类别:
-
资助金额:$8.24万
-
财政年份:2008
-
负责人:Richard M Longnecker
-
依托单位:
Discovery of New Treatment Options for EBV-associated Lymphoma and PTLD
-
批准号:7837601
-
项目类别:
-
资助金额:$27.42万
-
财政年份:2008
-
负责人:Richard M Longnecker
-
依托单位:
Discovery of New Treatment Options for EBV-associated Lymphoma and PTLD
-
批准号:8138301
-
项目类别:
-
资助金额:$13.44万
-
财政年份:2008
-
负责人:Richard M Longnecker
-
依托单位:
EBV gB Function in Viral Fusion, Entry, and Egress
-
批准号:7215035
-
项目类别:
-
资助金额:$36.32万
-
财政年份:2007
-
负责人:Richard M Longnecker
-
依托单位:
EBV gB Function in Viral Fusion, Entry, and Egress
-
批准号:8008764
-
项目类别:
-
资助金额:$37.07万
-
财政年份:2007
-
负责人:Richard M Longnecker
-
依托单位:
EBV gB Function in Viral Fusion, Entry, and Egress
-
批准号:7797000
-
项目类别:
-
资助金额:$4.07万
-
财政年份:2007
-
负责人:Richard M Longnecker
-
依托单位:
EBV gB Function in Viral Fusion, Entry, and Egress
-
批准号:7540958
-
项目类别:
-
资助金额:$36.53万
-
财政年份:2007
-
负责人:Richard M Longnecker
-
依托单位:
海外基金